TEZSPIRE (AstraZeneca Pty Ltd)
Product name
TEZSPIRE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
197 (255 working days)
Active ingredients
tezepelumab
Registration type
NCE/ NBE
Indication
TEZSPIRE is indicated as an add-on maintenance treatment in patients aged 12 years and older with severe asthma who are inadequately controlled despite optimal therapy including medium or high dose inhaled corticosteroids plus another non-steroidal medicinal product for maintenance treatment.